Vadodara: Alembic Pharmaceuticals is adding another regulated-market approval to its portfolio, reinforcing its presence in the US generics space with a key oncology and autoimmune therapy product.
Vadodara: Alembic Pharmaceuticals has strengthened its US generics portfolio with a key regulatory approval, positioning itself to tap into a high-value diabetes treatment market. Alembic ...
BEDMINSTER, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Alembic Therapeutics is pleased to announce the U.S. availability of Pivya ® (pivmecillinam) tablets, 185mg, an oral prescription antibiotic. Pivya ...
Feb 5 (Reuters) - Indian drugmaker Alembic Pharmaceuticals (ALEM.NS), opens new tab on Thursday reported lower third‑quarter profit on Thursday after taking a one-time charge linked to India's new ...
Alembic Pharmaceuticals Ltd on Monday said it has received tentative approval from the US health regulator for its Bosutinib tablets used in the treatment of certain types of cancer. The tentative ...
Alembic Pharmaceuticals Limited (Alembic), a vertically integrated research and development pharmaceutical company, announced that it has received final approval from the US Food & Drug Administration ...
Led by Prysm Capital and Accenture with participation from Silver Lake Waterman, Liquid 2 Ventures, NextEquity, Friends & Family Capital, and WndrCo, this round positions Alembic among the top AI labs ...
Alembic Pharmaceuticals Share Price | The tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. Alembic Pharmaceuticals share price rose 2 percent ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Alembic Pharmaceuticals Limited (Alembic), a vertically integrated research and development pharmaceutical company, announced that it has received final approval from the US Food & Drug Administration ...
Alembic Technologies raises $145M and buys an Nvidia-powered supercomputer to accelerate ‘causal AI’
Causal artificial intelligence startup Alembic Technologies Inc. said today it has raised $145 million in a Series B growth round that increases its valuation almost 16-fold. It’s using a big chunk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results